COMMUNIQUÉS West-GlobeNewswire

TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
07/05/2024
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its [...]
Capital Increase in Genmab as a Result of Employee Warrant Exercise
07/05/2024
Company Announcement COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. The increase is effected without [...]
Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
07/05/2024
Michael Heltzen appointed as CEO bringing 20 years of global commercial leadership experience and a track record of successful launches and exits Additional industry veterans join in key roles including business [...]
WAKE RADIOLOGY SUPPORTS TRIANGLE RACE FOR THE CURE WITH THIRD LARGEST TEAM, $11,100 CONTRIBUTION
07/05/2024
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Wake Radiology UNC REX Healthcare, the oldest and largest outpatient imaging provider in the Triangle, contributed $11,100 to breast cancer research as a [...]
Correction: NTG Nordic Transport Group publishes interim report for Q1 2024
07/05/2024
Company announcement no. 5 – 24 7 May 2024 NTG Nordic Transport Group publishes interim report for Q1 2024 The interim report for Q1 2024 is enclosed. In connection with publication of the results for Q1 2024, a [...]
EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT®
07/05/2024
EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT® Expansion in the oncology segment Development of Eurobio Scientific proprietary product portfolio Increase of [...]
EUROBIO SCIENTIFIC SIGNE UN ACCORD POUR L'ACQUISITION DU TEST D'EXPRESSION GÉNIQUE POUR LE CANCER DU SEIN ENDOPREDICT®
07/05/2024
EUROBIO SCIENTIFIC SIGNE UN ACCORD POUR L'ACQUISITION DU TEST D'EXPRESSION GÉNIQUE POUR LE CANCER DU SEIN ENDOPREDICT® Expansion dans le segment de l'oncologie Développement du portefeuille de produits propriétaires d' [...]
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
07/05/2024
ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision: significant reduction [...]
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
07/05/2024
PRESS RELEASE A NEW PUBLICATION IN THE MEDICAL JOURNAL MUSCLE & NERVE VALIDATES THE USE OF THE RATE OF DECLINE OF ALSFRS-R SCORE (ΔFS) FOR THE DESIGN OF CLINICAL STUDIES AND THE TREATMENT CHOICE FOR AMYOTROPHIC [...]
AB Science:
07/05/2024
COMMUNIQUE DE PRESSE UNE NOUVELLE PUBLICATION DANS LA REVUE MÉDICALE MUSCLE & NERVE VALIDE L’UTILISATION DU DECLIN DU SCORE ALSFRS-R (ΔFS) POUR LE DESIGN DES ETUDES CLINIQUES ET LE CHOIX DE TRAITEMENT DES PATIENTS [...]
Philips shareholders approve all proposals at the AGM 2024
07/05/2024
May 7, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2024, including: The re- [...]
NTG Nordic Transport Group publishes interim report for Q1 2024
07/05/2024
Company announcement no. 5 – 24 7 May 2024 NTG Nordic Transport Group publishes interim report for Q1 2024 The interim report for Q1 2024 is enclosed. In connection with publication of the results for Q1 2024, a [...]
New Discovery Identifies “Don’t Eat Me” Protein that Allows Lyme Bacteria to Evade Body’s Immune Response
07/05/2024
Stanford University/MIT/UCSF study funded by Bay Area Lyme Foundation offers new direction for tick-borne disease research, paving the way for potential new discoveries PALO ALTO, Calif., May 07, 2024 (GLOBE NEWSWIRE [...]
Ibogaine By David Dardashti Launches New Software for Treatment Dose
07/05/2024
Optimizing Precision and Efficiency with Innovative Software MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti is proud to announce the launch of their new treatment dose software, designed to optimize [...]
Syntekabio to Showcase Biologics Discovery Platform at PEGS Boston
07/05/2024
Company offering discovery services for neoantigens with Neo-ARS and for full antibodies with Ab-ARS NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug [...]
Successful FDA Inspection at Dipharma Facility in Kalamazoo, MI, USA
07/05/2024
The Company expands its range of CGMP services to include small-scale commercial APIs MILAN, Italy, May 07, 2024 (GLOBE NEWSWIRE) -- Dipharma Francis S.r.l. (Dipharma), a global Contract Development and Manufacturing [...]
Teknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy Development
07/05/2024
First-of-its-kind custom configurator – available today – gives scientists access to high quality, customizable buffers in small volumes for use in early-stage experiments, all with exceptionally short turnaround times [...]
FibroBiologics to Present at the BIO International Convention 2024
07/05/2024
HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of [...]
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
07/05/2024
- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated - Limited Number of [...]

Pages